Review

sas version 8.2 (SAS institute)

SAS institute is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

SAS institute sas version 8.2
Sas Version 8.2, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sas+version+8%2E2/sas+version+9+4/pm40551566-99-6-9
Average 90 stars, based on 1 article reviews

sas version 8.2 - by Bioz Stars, 2026-10

90/100 stars

Images

other:

Article Title: Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria
Article Snippet: The frequency of adverse events stratified by dose cohort was summarized (SAS Version 8.2, Cary, NC).

Article Title: Long-Term Efficacy and Tolerability of an Emollient Containing Glycerol and Paraffin for Moderate-to-Severe Uremic Xerosis: A Randomized Phase 3 Study.
Article Snippet: A significance level of 5% was applied to all statistical tests, which were performed using SAS version 8.2 (SAS Institute Inc., Cary, NC, USA).

Article Title: Clinical Outcomes, Healthcare Utilization, and Cost Following Implementation of a High-Sensitivity Cardiac Troponin Assay.
Article Snippet: Analyses were done using SAS version 8.2 and R version 3.6.0.

Article Title: Prospective Evaluation of Missed Musculoskeletal Injuries in Trauma Prevent Study.
Article Snippet: All statistical analyses were performed using SAS version 8.2 (SAS Inc, Cary, NC).

Article Title: JTT-654, an 11-beta hydroxysteroid dehydrogenase type 1 inhibitor, improves hypertension and diabetic kidney injury by suppressing angiotensinogen production.
Article Snippet: Statistical analyses were performed using SAS version 8.2 (SAS Institute Inc., CA, USA).

Article Title: Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria
Article Snippet: Statistical procedures The frequency of adverse events stratified by dose cohort was summarized (SAS Version 8.2, Cary, NC).

Article Title: Dermatological manifestations in Costello syndrome: A prospective multicentric study of 31 HRAS-positive variant patients.
Article Snippet: Statistical analysis was performed using SAS® version 8.2 (SAS Enterprise Guide).

Article Title: Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes.
Article Snippet: Statistical calculations were performed using SAS version 8.2.

Review

sas version 8.2 (SAS institute)

Structured Review

Images

Related Articles

other:

Similar Products

Image Search Results